Dementia poses a major health challenge with no safe, affordable treatments to slow its progression. Researchers at Lawson ...

A landmark study by London researchers investigating the use of a cough medicine called Ambroxo to slow the progression of ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...

A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

New research finds that diet, exercise, and stress management helped improve or stabilize brain function in early-stage ...

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.